Cancer Immuno-therapy Opportunities

Immuno-Modulatory Therapeutic Antibodies

C1198  Methods for the Modulation of Immune Responses using Galectin-1 (PCT/US2008/070324)
Margaret Shipp, M.D.

C1316  Anti-Galectin-1 Monoclonal Antibodies (PCT/US2010/056547)
Margaret Shipp, M.D.

C1999  Novel PD-L2 Monoclonal Antibodies (Provisional Filed)
Gordon Freeman, Ph.D.

C2000  Novel PD-L1 Monoclonal Antibodies with High Affinity (Provisional Filed)
Gordon Freeman, Ph.D.

Diagnostic and Prognostic Biomarkers

C1764  A diagnostic galectin-1 monoclonal antibody (PCT/US2014/047783)
Margaret Shipp, M.D.

Gordon Freeman, Ph.D.

C1836, C1835, C1834 High Affinity PD-1, PD-L1, PD-L2 Monoclonal Antibodies for Diagnostics
Gordon Freeman, Ph.D.

C1807  PDL1 as a Biomarker (PCT/US2015/011303)
F. Stephen Hodi, M.D.

C1871  Measurement of PD-1 Pathway Activation Using an Anti-phosphotyrosine PD-1 mAb
Gordon Freeman, Ph.D.

C1880  Novel Biomarker for Sensitivity to PD-L1 Targeted Therapy (PCT/US2015/032823)
Kwok-Kin Wong, M.D., Ph.D. • David Barbie, M.D.

C1947  Circulating Angiopoietin-2 as a Predictive Biomarker for Response to Cancer Immune Therapy (PCT/US2015/053933)
F. Stephen Hodi, M.D.

F. Stephen Hodi, M.D.

For more information, please contact the Innovation Office at DFCI:
innovation@dfci.harvard.edu
Cancer Immuno-therapy Opportunities

Cancer Vaccine

C0376  Tumor Cells Modified with Increased Immunogenicity (US6723705, US5861310)
Gordon Freeman, Ph.D.  ♦  Lee Nadler, M.D.

Adoptive Cell Transfer Therapy

Gordon Freeman, Ph.D.  ♦  Lee Nadler, M.D.

Gordon Freeman, Ph.D.  ♦  Lee Nadler, M.D.

Drug Delivery

C2117  Nanoparticles that Target Immunotherapy to Specific Subsets of Endogenous Immune Cells (PCT Filed)
Michael Goldberg, Ph.D.

For more information, please contact the Innovation Office at DFCI:
innovation@dfci.harvard.edu